Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

Paul G. Richardson,William Bensinger,Katja Weisel,Kevin Boyd,Karthik Ramasamy,Esther Mena Gonzalez,Linda Favre-Kontula,Teresa Peluso,Lars Sternas,Carl Di Casoli,Mohamed H. Zaki,Thierry Facon

Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

2017

Paul G. Richardson
William Bensinger
Katja Weisel
Kevin Boyd
Karthik Ramasamy
Esther Mena Gonzalez
Linda Favre-Kontula
Teresa Peluso
Lars Sternas
Carl Di Casoli
Mohamed H. Zaki
Thierry Facon

TPS8054Background: DARA, a monoclonal antibody (mAb) against CD38, is approved for RRMM. Combination treatment (Tx) with DARA + DURVA, a mAb against programmed death ligand-1 (PD-L1), may enhance h...

Keywords:

Daratumumab
Refractory Multiple Myeloma
Pathology
Dara
Oncology
Durvalumab
Medicine
Internal medicine
combined treatment
in patient
programmed death
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations